GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Neurotech International Ltd (ASX:NTI) » Definitions » Net Cash per Share

Neurotech International (ASX:NTI) Net Cash per Share : A$0.00 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Neurotech International Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Neurotech International's Net Cash per Share for the quarter that ended in Dec. 2023 was A$0.00.

The historical rank and industry rank for Neurotech International's Net Cash per Share or its related term are showing as below:

During the past 7 years, the highest Price-to-Net-Cash Ratio of Neurotech International was 14.00. The lowest was 5.30. And the median was 8.95.

ASX:NTI's Price-to-Net-Cash is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 7.05
* Ranked among companies with meaningful Price-to-Net-Cash only.

Neurotech International Net Cash per Share Historical Data

The historical data trend for Neurotech International's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurotech International Net Cash per Share Chart

Neurotech International Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Cash per Share
Get a 7-Day Free Trial - - 0.01 - -

Neurotech International Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.01 - -

Competitive Comparison of Neurotech International's Net Cash per Share

For the Medical Devices subindustry, Neurotech International's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Neurotech International's Price-to-Net-Cash Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Neurotech International's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Neurotech International's Price-to-Net-Cash falls into.



Neurotech International Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Neurotech International's Net Cash per Share for the fiscal year that ended in Jun. 2023 is calculated as

Net Cash per Share (A: Jun. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(5.026-1.347-0)/873.909
=0.00

Neurotech International's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

Net Cash per Share (Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(4.479-0.276-0)/891.739
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Neurotech International  (ASX:NTI) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Neurotech International Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Neurotech International's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Neurotech International (ASX:NTI) Business Description

Traded in Other Exchanges
N/A
Address
145 Stirling Highway, Suite 5 CPC, Nedlands, WA, AUS, 6009
Neurotech International Ltd is a medical device and solutions company. It researches, designs, markets, and produces wearable neurotechnology devices to assist with neurological conditions such as autism. Geographically, all the business activities of the firm function through the region of Australia. It operates in one segment named Medical Device Development and Distribution.

Neurotech International (ASX:NTI) Headlines

From GuruFocus

How to Capitalize on the Bakken Oil Boom

By Vitaliy Katsenelson Vitaliy Katsenelson 11-09-2013

9 Stocks With Yields Over 10% And Buy Or Better Rating

By Dividend Dividend 08-17-2013

13 Stocks With Dividend Yields Over 10%

By Dividend Dividend 11-12-2014

20 Stocks with Yields over 10% and Highest Buy Ratings

By Dividend Dividend 01-17-2013